depresja24h napisał(a):Lek ten jest dostępny w Hiszpanii i Anglii. Można poszukać polskiego psychiatry pracującego tam, zadzwonić i zapytać się czy wystawiłby receptę, pojechać.
Remission rates were not significantly different between the two treatment groups (6.9% for the tranylcypromine group and 13.7% for the venlafaxine plus mirtazapine group).
No difference in efficacy was observed between both monoamine oxidase inhibitors [phenelzine and tranylcypromine] in a sample of patients with severe antidepressant-refractory depression.
Response to the two drugs was similar, with an overall average reduction in scores on the Hamilton Rating Scale for Depression of about 50% over 6 weeks. Improvement was negatively correlated with initial severity of depression, especially in patients treated with desipramine. Response to desipramine was better in patients with moderate to severe stressors and no previous hospitalizations.
...this replicates acute trials demonstrating imipramine's relative ineffectiveness in patients with atypical depression.
The rates of treatment response did not differ between groups. It was concluded that fluoxetine is as effective as phenelzine in the treatment of atypical depression, but produces fewer adverse effects and is better tolerated.
These data suggest that among chronically ill, mood-reactive depressed patients with many symptoms of atypical depression, phenelzine is strikingly effective in those who have been nonresponders to imipramine and should be tried in such patients.
Significantly more patients responded to phenelzine (71%) than to imipramine (48%).
In contrast to the atypical depressives for whom phenelzine was effective and imipramine was relatively ineffective, both medications were equivalently good in simple mood reactive depressives.
Phenelzine was found to be superior to imipramine and placebo.
Both drugs were found to be equally efficacious in the treatment of 32 patients suffering from Major Depression. In 32 Dysthymic patients, phenelzine in high doses was found to be superior to imipramine. The clinical implications of these findings are discussed.
Nortriptyline and phenelzine were more effective than placebo in treating depression mood, guilt feelings, suicidal ideation, agitation, anxiety, loss of energy, and a.m. diurnal variation of mood. Nortriptyline was better than phenelzine or placebo in improving middle/late insomnia.
Phenelzine was superior to imipramine on the interpersonal sensitivity and paranoia factors of the 90-item Hopkins Symptom Checklist, with trends toward superiority on several other measures, while imipramine was not differentially superior on any measure.
There was a tendency for phenelzine to have stronger effects in patients with additional anxiety and without evidence of chronic characterological depression.
There were additional weak differences, phenelzine producing more improvement on anxiety ratings, while amitriptyline gave greater effects on depressive impairment of work and interests and anergia. The findings indicate that MAO inhibitors and tricyclic antidepressants have more closely similar clinical effects than has been thought and that either may be a useful treatment for these patients who are often considered to respond poorly to antidepressant drug treatment.
Imipramine did not give results which were significantly better than phenelzine.
After three weeks treatment, the two drugs were equally effective on Hamilton, Beck and SCL-90 measures of depression and anxiety. On the the SCL-90 scales of hostility and paranoia imipramine was more effective; in some patients phenelzine was associated with increased hostility.
By the 5th week, with MAO inhibition greater than 90%, phenelzine was significantly more effective than amitriptyline. A highly significant correlation was noted between improvement and MAO inhibition within the phenelzine group.
The results show both antidepressants to be effective, with the similarities between the two exceeding the differences. Both drugs had marked antidepressant and antianziety effects. Phenelzine tended to exert a stronger antianxiety action; amitriptyline was more effective in reversing weight loss and improving sleep.
On the clinical manifestation of agitation and anxiety, however, phenelzine was significantly better than both dexamphetamine and lactose; dexamphetamine was again no better than lactose. The findings suggest that the beneficial effect of pheneizine in depressive illness is due more to a sedative action in relieving anxiety than to a specific antidepressive action.
The overall effect size of pharmacotherapy for SAD is small to medium (Hedges's g = 0.39). The most effective pharmacotherapy type was phenelzine (Hedges's g = 1.14), followed by paroxetine (Hedges's g = 0.49), venlafaxine ER (Hedges's g = 0.45) and moclobemide (Hedges's g = 0.23).
It is concluded that pharmacotherapy is effective for treating SAD, but there is considerable variation and room for further improvement.
Użytkownicy przeglądający ten dział: AlexCCC, Google [Bot] i 50 gości